Goldberg Terry E, Huey Edward D, Devanand Davangere P
Department of Psychiatry, Columbia University Irving Medical Center, New York, New York, USA
Psychiatry and Anesthesiology, Columbia University Irving Medical Center, New York, New York, USA.
J Neurol Neurosurg Psychiatry. 2020 Nov 4. doi: 10.1136/jnnp-2020-323746.
We assessed the association of apolipoprotein E (APOE) genotype with cerebrovascular disease (CVD) in a large neuropathological database maintained by the National Alzheimer's Coordinating Center (NACC). Such a comprehensive investigation of APOE and CVD pathology has not heretofore been conducted. We focused on APOE e2, an established neuroprotective genetic variant against Alzheimer's disease.
To implement these objectives APOE associations in the NACC database of 1275 brains with 11 CVD pathologies, including old and recent infarcts, haemorrhages, cerebral amyloid angiopathy (CAA) and arteriosclerosis, were examined. These pathologies were uniformly and semiquantitatively measured across 39 Alzheimer's Disease Center sites. We used χ2 statistics and ordinal regression to assess the significance of associations and Bonferroni corrected for multiple comparisons.
Of the cases, 98 were e2/e3 or e2/e2 genotypes ('e2' carriers), 621 were e3 homozygotes ('e3' group), and 556 were e4/e3 (442) or e4/e4 (114) genotypes ('e4' group). Results indicated that the APOE e4 allele significantly increased risk for CAA. After stratification by CAA presence/absence, we found that in those cases in which CAA was present, APOE e2 significantly increased risk for gross haemorrhage. All other associations were negative.
In this, the largest study of APOE e2 effects on pathologically verified CVD, e2 was not protective against any CVD pathology compared with e3 homozygotes, including CAA. Regarding the latter pathology, e4 was associated with increases in its severity. Furthermore, and perhaps unexpectedly, e2 significantly increased risk of acute/subacute gross haemorrhage in the presence of CAA. Thus, there were limits to e2 neuroprotection against amyloidosis, despite its known and large protective effects against diffuse and neuritic amyloid plaques compared with e3/e3 and e4 carriers in this very collection.
我们在由国家阿尔茨海默病协调中心(NACC)维护的大型神经病理学数据库中评估了载脂蛋白E(APOE)基因与脑血管疾病(CVD)之间的关联。此前尚未进行过如此全面的APOE与CVD病理学研究。我们重点关注APOE ε2,这是一种已确定的对阿尔茨海默病具有神经保护作用的基因变异体。
为实现这些目标,我们在NACC数据库中检查了1275个大脑的APOE关联情况,这些大脑存在11种CVD病理学特征,包括陈旧性和近期梗死、出血、脑淀粉样血管病(CAA)和动脉硬化。这些病理学特征在39个阿尔茨海默病中心站点进行了统一和半定量测量。我们使用χ²统计量和有序回归来评估关联的显著性,并采用Bonferroni法对多重比较进行校正。
在这些病例中,98例为ε2/ε3或ε2/ε2基因型(“ε2”携带者),621例为ε3纯合子(“ε3”组),556例为ε4/ε3(442例)或ε4/ε4(114例)基因型(“ε4”组)。结果表明,APOE ε4等位基因显著增加了CAA的风险。在按CAA存在与否进行分层后,我们发现,在存在CAA的病例中,APOE ε2显著增加了大出血的风险。所有其他关联均为阴性。
在这项关于APOE ε2对经病理证实的CVD影响的最大规模研究中,与ε3纯合子相比,ε2对任何CVD病理学特征均无保护作用,包括CAA。关于后者的病理学特征,ε4与其严重程度增加相关。此外,或许出人意料的是,在存在CAA的情况下,ε2显著增加了急性/亚急性大出血的风险。因此,尽管在这个样本中,与ε3/ε3和ε4携带者相比,ε2对弥漫性和神经炎淀粉样斑块具有已知的且很大的保护作用,但它对淀粉样变性的神经保护作用是有限的。